Abstract
Background: The short (S) allele of the serotonin transporter gene-linked polymorphic region (5HTTLPR) has been associated with poorer antidepressant response in major depressive disorder (MDD) and with antidepressant-induced mania. This study investigated a possible association with treatment-emergent insomnia or agitation. Methods: Thirty-six outpatients with MDD were genotyped at 5HTTLPR and treated with open-label fluoxetine up to 60 mg/day. Treatment-emergent adverse effects were assessed at each study visit. Results: Of nine subjects homozygous for the "S" allele, seven (78%) developed new or worsening insomnia, versus 6 of 27 (22%) non-"S"-homozygous subjects (Fisher's exact p = .005). Similarly, six of nine subjects homozygous for the "S" allele (67%) developed agitation, versus 2 of 27 (7%) of non-"S"-homozygous subjects (Fisher's exact p = .001). Conclusions: The "S" allele of the 5HTTLPR may identify patients at risk for developing insomnia or agitation with fluoxetine treatment. This preliminary result requires confirmation in larger samples.
Original language | English (US) |
---|---|
Pages (from-to) | 879-883 |
Number of pages | 5 |
Journal | Biological Psychiatry |
Volume | 54 |
Issue number | 9 |
DOIs | |
State | Published - Nov 1 2003 |
Keywords
- Adverse event
- Agitation
- Depression
- Fluoxetine
- Insomnia
- Serotonin transporter
ASJC Scopus subject areas
- Biological Psychiatry